- Home
- CYH vs CMPS Comparison
CYH vs CMPS Comparison
Compare CYH & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- CMPS
- Stock Information
- Founded
- CYH 1985
- CMPS 2020
- Country
- CYH United States
- CMPS United Kingdom
- Employees
- CYH 61000
- CMPS N/A
- Industry
- CYH Hospital/Nursing Management
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- CMPS Health Care
- Exchange
- CYH Nasdaq
- CMPS Nasdaq
- Market Cap
- CYH 487.7M
- CMPS 422.4M
- IPO Year
- CYH 1991
- CMPS 2020
- Fundamental
- Price
- CYH $3.52
- CMPS $4.21
- Analyst Decision
- CYH Hold
- CMPS Strong Buy
- Analyst Count
- CYH 7
- CMPS 6
- Target Price
- CYH $4.18
- CMPS $29.60
- AVG Volume (30 Days)
- CYH 2.8M
- CMPS 1.2M
- Earning Date
- CYH 02-18-2025
- CMPS 02-27-2025
- Dividend Yield
- CYH N/A
- CMPS N/A
- EPS Growth
- CYH N/A
- CMPS N/A
- EPS
- CYH N/A
- CMPS N/A
- Revenue
- CYH $12,634,000,000.00
- CMPS N/A
- Revenue This Year
- CYH $1.23
- CMPS N/A
- Revenue Next Year
- CYH $1.75
- CMPS N/A
- P/E Ratio
- CYH N/A
- CMPS N/A
- Revenue Growth
- CYH 1.15
- CMPS N/A
- 52 Week Low
- CYH $2.60
- CMPS $3.17
- 52 Week High
- CYH $6.29
- CMPS $12.75
- Technical
- Relative Strength Index (RSI)
- CYH 57.57
- CMPS 48.38
- Support Level
- CYH $3.11
- CMPS $3.99
- Resistance Level
- CYH $3.79
- CMPS $4.88
- Average True Range (ATR)
- CYH 0.22
- CMPS 0.41
- MACD
- CYH 0.02
- CMPS -0.01
- Stochastic Oscillator
- CYH 62.84
- CMPS 26.89
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.